MedDataX Logo

Modulated Electro-Hyperthermia Plus Chemo-radiation for Locally Advanced Cervical Cancer Patients in South Africa

NCT ID: NCT03332069

Last Updated: 2017-11-07

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE3

Total Enrollment

236 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-01-09

Study Completion Date

2020-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a phase III randomised clinical trial. The aim is to investigate the clinical effects of the addition of modulated electro-hyperthermia (mEHT) to standard treatment protocols (chemoradiotherapy, CRT) for Human Immunodeficiency Virus (HIV) positive and negative locally advanced cervical cancer patients (LACC). SAMPLE: The investigators aim to enrol 236 HIV negative and HIV positive women with LACC, FIGO (Fédération Internationale de Gynécologie et d'Obstétrique) Stages IIB (distil) to stage III. Participants will be randomly assigned to a control group (N=118) and a study group (N=118). METHODOLOGY: Randomisation is based on age, stage and HIV. Participants from both groups will receive the standard treatment for cervical cancer at the hospital at the Charlotte Maxeke Johannesburg Academic Hospital in South Africa: Up to three doses of 80mg/m2 cisplatin, administered three weeks apart; 50Gy external beam radiation (EBR) in fractions of 2Gy; Three doses of 8Gy High Dose Rate (HDR) brachytherapy. The study group will have two 55 minute mEHT treatments per week, at 130W, directly before the EBR using the EHY 2000 Device. OUTCOMES: 1) Determine the local disease control after treatment at 6 months using a Positron Emission Tomography (PET) and computerised tomography (CT) scans. 2) Determine the progression-free survival (PFS) at 6, 12, 18 and 24 months after the last treatment date. PFS will be assessed in all registered participants, regardless of completion (Intent to Treat-ITT) as well as only in the subset of participants who complete the prescribed CRT. 3) Overall survival at two years will be assessed. 4) To evaluate the adverse events associated with mEHT. 5) The effect of mEHT on chemotherapy and radiotherapy tolerability and toxicity will be evaluated. 6) The quality of life of enrolled participants will be assessed before, at 6 weeks, and at 3, 6, 9, 12, 18 and 24 months after completion of therapy using the EORTC (European Organisation for Research and Treatment of Cancer) and EuroQoL forms. 7) To evaluate the economic viability of the addition of mEHT to standard treatment protocols for LACC. 8) The effect, if any, of mEHT treatments on the HIV disease status of HIV positive patients will be assessed by the presence of Autoimmune Deficiency Syndrome (AIDS) defining illnesses before and after treatment. 9) The cancer recurrence patterns will be described and compared in all the participants.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cervical Cancer

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Hyperthermia cervix HIV

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Caregivers Outcome Assessors
Clinicians conducting follow up evaluations, radiographers and nuclear medicine physicians reporting on the PET/CT investigations are unaware of the group that the participants have been assigned to.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Study

50 Gy external beam radiation administered in fractions of 2 Gy 3 Doses of 8 Gy High Dose Rate brachytherapy up to 3 doses of 80mg/m2 of Cisplatin 10 modulated electro-hyperthermia treatments (55 minutes at a maximum of 150W)

Group Type EXPERIMENTAL

Modulated electro-hyperthermia

Intervention Type DEVICE

Modulated electro-hyperthermia device used is the EHY 2000 by Oncotherm GmbH

External beam radiation

Intervention Type RADIATION

Cisplatin

Intervention Type DRUG

Brachytherapy

Intervention Type RADIATION

High Dose Rate

Control

50 Gy external beam radiation administered in fractions of 2 Gy 3 Doses of 8 Gy High Dose Rate brachytherapy up to 3 doses of 80mg/m2 of Cisplatin

Group Type ACTIVE_COMPARATOR

External beam radiation

Intervention Type RADIATION

Cisplatin

Intervention Type DRUG

Brachytherapy

Intervention Type RADIATION

High Dose Rate

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Modulated electro-hyperthermia

Modulated electro-hyperthermia device used is the EHY 2000 by Oncotherm GmbH

Intervention Type DEVICE

External beam radiation

Intervention Type RADIATION

Cisplatin

Intervention Type DRUG

Brachytherapy

High Dose Rate

Intervention Type RADIATION

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Oncothermia Nanothermia Radiotherapy Chemotherapy Radiation therapy

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Participants (who have been adequately clinically staged by standard clinical guidelines) with biopsy proven primary, untreated, histologically confirmed invasive squamous and aden-squamous cell carcinoma of the uterine cervix, FIGO (Fédération Internationale de Gynécologie et d'Obstétrique) stages advanced IIB (invasion of the distal half of the parametrium), IIIA and IIIB.
2. HIV positive participants will be accepted.
3. The following laboratory tests will be done prior to enrolment in the study and the values must be in the following ranges:

* Haemoglobin \>10 g/dL;
* Platelet count \>150/mm3;
* Absolute neutrophil count (ANC) \>3000/mm3
* Creatinine clearance\>60 mL/min
* Liver function tests
4. Females between the ages of 18 and 70 years.
5. Ability to understand and the willingness to sign a written informed consent document.
6. Eastern Cooperative Oncology Group (ECOG) score of not more than 2.
7. Participants of childbearing potential must have a negative urine or serum pregnancy test prior to enrolment and use an effective form of contraception (e.g. barrier contraception, highly effective hormonal contraception).
8. At the investigators' discretion, participants must be suitable for treatment with radical intent using concurrent chemotherapy and pelvic radiation. Subjects who undergo emergency RT in the form of brachytherapy for haemostasis, prior to enrolment will be allowed to be screened and enrolled provided they meet all other eligibility criteria.
9. Life expectancy of greater than 12 months.
10. Participants must have a body mass index (BMI) that is within normal ranges.

\-

Exclusion Criteria

1. Participants who have undergone hysterectomy.
2. Exclude para-aortic lymph involvement on planning CT (without contrast)
3. Patients with life-threatening AIDS defining illnesses (other than cervical carcinoma) will be excluded, as will patients with a CD4 count \< 200/µL and not on ARVs.
4. Patients with acute active (such as tuberculosis or malaria), serious, uncontrolled infections will be excluded.
5. Participants will be excluded if there is evidence of resistance to antiretroviral therapy (i.e. HIV viral load \> 400 copies/mL despite combination antiretroviral therapy for at least 4 months).
6. Prior invasive malignancy other than cervical cancer, diagnosed within the past 24 months, excluding in situ anal dysplasia or carcinoma in situ, non-melanoma skin carcinoma, or Kaposi's sarcoma that has not required systemic chemotherapy within the past 24 months.
7. Pregnant or breast-feeding women.
8. A medical or psychiatric illness that prevents the participant from being able to sign an informed consent or would affect the participant's ability to comply with the protocol stipulations.
9. Participants with circumstances that will not permit completion of the study or required follow-ups. For instance if travel to and from treatment site is an issue.
10. Participants with carcinoma of the cervical stump.
11. Participants with a history of cardiovascular disease manifested as

1. History of myocardial infarction
2. Unstable angina
3. Currently taking medication for treatment of angina
4. History of coronary artery bypass surgery
12. Participants with contraindications to modulated electro-hyperthermia treatment:

1. Pace makers and other implanted devices which rely on current and charges.
2. Large metal implants, such as hip replacements.
3. Inability to feel temperature in the region.
4. Inability to express or vocalise discomfort or heat at the treatment site.
Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

National Research Foundation of South Africa

OTHER

Sponsor Role collaborator

NTP Radioisotopes SOC Ltd

UNKNOWN

Sponsor Role collaborator

Jeffrey Kotzen

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Jeffrey Kotzen

Senior Radiation Oncologist

Responsibility Role SPONSOR_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Carrie A Minnaar, Msc

Role: STUDY_CHAIR

Student - PhD Candidate

Jeffrey A Kotzen, MBBCH

Role: PRINCIPAL_INVESTIGATOR

Senior Radiation Oncologist

Ans Baeyes, PhD

Role: STUDY_CHAIR

Head of Department of Radiobiology

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Charlotte Maxeke Johannesburg Academic Hospital

Johannesburg, Gauteng, South Africa

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

South Africa

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Carrie A Minnaar, PhD student

Role: CONTACT

Phone: +27721234292

Email: [email protected]

Jeffrey A Kotzen, MBCHB

Role: CONTACT

Phone: +27825747985

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Jeffrey A Kotzen, MBBCH

Role: primary

Carrie A Minnaar, Masters

Role: backup

References

Explore related publications, articles, or registry entries linked to this study.

Fiorentini G, Szasz A. Hyperthermia today: electric energy, a new opportunity in cancer treatment. J Cancer Res Ther. 2006 Apr-Jun;2(2):41-6. doi: 10.4103/0973-1482.25848.

Reference Type BACKGROUND
PMID: 17998673 (View on PubMed)

van der Zee J, Gonzalez GD. The Dutch Deep Hyperthermia Trial: results in cervical cancer. Int J Hyperthermia. 2002 Jan-Feb;18(1):1-12. doi: 10.1080/02656730110091919.

Reference Type BACKGROUND
PMID: 11820462 (View on PubMed)

Minnaar CA, Kotzen JA, Naidoo T, Tunmer M, Sharma V, Vangu MD, Baeyens A. Analysis of the effects of mEHT on the treatment-related toxicity and quality of life of HIV-positive cervical cancer patients. Int J Hyperthermia. 2020;37(1):263-272. doi: 10.1080/02656736.2020.1737253.

Reference Type DERIVED
PMID: 32180481 (View on PubMed)

Minnaar CA, Kotzen JA, Ayeni OA, Naidoo T, Tunmer M, Sharma V, Vangu MD, Baeyens A. The effect of modulated electro-hyperthermia on local disease control in HIV-positive and -negative cervical cancer women in South Africa: Early results from a phase III randomised controlled trial. PLoS One. 2019 Jun 19;14(6):e0217894. doi: 10.1371/journal.pone.0217894. eCollection 2019.

Reference Type DERIVED
PMID: 31216321 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

LACC-OT

Identifier Type: -

Identifier Source: org_study_id